Sundyota Numandis, a global health oriented organisation based in Ahmedabad, has signed a pact with global probiotic leader Probiotical of Italy to offer world's most researched probiotic product Lactobacillus rhamnosus GG in the Indian market.
Dinesh Arora, MD and CEO of the Sundyota Numandis Group of Companies, said in Ahmedabad on Wednesday that the product procured would be strategically marketed by Sundyota Numandis and Cipla, a leading pharma company in the country.
According to Arora, L. rhamnosus GG has been a preferred choice of healthcare professions for various health conditions, particularly gastrointestinal complaints like diarrhea, irritable bowel syndrome and inflammatory bowel disease.
Arora said that as part of the pact, Sundyota Numandis procures coated oro-soluble L. rhamnosus GG from Probiotical and undertakes its manufacturing for the Indian market. It has introduced the product under the brand name of “SuperFlora GG”.
It has also entered into a strategic alliance with Cipla for parallel launch and co-marketing of the same product. It is named “Unobiotics”. Both SuperFlora GG and Unobiotics are available in the market. These brand names are available under Microbac GG technology under which the oro-dispersible powder form is stable in the Indian climate.
Making a mention that probiotics were to become the mainstay in the future, Arora said that currently the Indian probiotic market was valued at around Rs 1,000 crore and was growing at a rate of 15 per cent.
Arora said that they were hoping that within 12 months of the launch, Microbac GG would attain a value of Rs 30 crore.
Claiming that probiotics had no side effects, he said that one dosage had to be taken daily.
In addition to this strategic tie up, the company is all set to open a new plant at a cost of Rs 80 crore at Changodar near Ahmedabad. The capacity of the plant would be to produce 51 crore sachets per year, in addition to probiotics in other forms.